0A3M.L
BioNTech SE News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 7,
"returned": 7,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "55f146c6-eb71-46c0-8cfa-44b494cce8c6",
"title": "BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session - BioNTech (NASDAQ:BNTX)",
"description": "",
"keywords": "",
"snippet": "Loading... Loading...\n\nU.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Monday.\n\nShares of BioNTech SE BNTX fell sha...",
"url": "https://www.benzinga.com/news/24/05/38638441/biontech-reports-downbeat-earnings-joins-medical-properties-trust-and-other-big-stocks-moving-lower",
"image_url": "https://cdn.benzinga.com/files/images/story/2024/05/06/xrdDAFefWvBGaQ2-j1684620644-t23032813.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2024-05-06T11:32:06.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "0A3M.L",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 20.265982,
"sentiment_score": -0.0258,
"highlights": [
{
"highlight": "Shares of <em>BioNTech</em> <em>SE</em> BNTX fell sharply in today's pre-market trading following weaker-than-expected first-quarter earnings.\n\nBioNTech posted quarterly GAAP loss of €1.31 per share, missing estimates of €0.97 per share. The company's sales came in at €187.600 million missing estimates of €427.500 million.",
"sentiment": -0.0258,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "42d8bf98-498f-409b-a30f-2504f4c98d08",
"title": "BioNTech shares dip 2% on earnings and revenue miss By Investing.com",
"description": "BioNTech shares dip 2% on earnings and revenue miss",
"keywords": "",
"snippet": "MAINZ, Germany - Shares of BioNTech SE (NASDAQ: ) fell 2.2% following the announcement of the first quarter financial results, which missed analyst expectations...",
"url": "https://www.investing.com/news/stock-market-news/biontech-shares-dip-2-on-earnings-and-revenue-miss-93CH-3420490",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPEB0E0CQ_L.jpg",
"language": "en",
"published_at": "2024-05-06T11:10:13.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "0A3M.L",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 20.265982,
"sentiment_score": -0.5106,
"highlights": [
{
"highlight": "MAINZ, Germany - Shares of <em>BioNTech</em> <em>SE</em> (NASDAQ: ) fell 2.2% following the announcement of the first quarter financial results, which missed analyst expectations.\n\nThe company reported a loss per share of €1.31 ($1.421), €0.18 worse than the analyst estimate of a €1.13 loss per share.",
"sentiment": -0.5106,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "28dc4d07-5aac-4718-9fa4-5623d1365379",
"title": "Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young' - Invesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (AR",
"description": "U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports continue to support the market, with S&P 500 earnings expected to grow by 5% year-over-year — the highest rate since Q2 2022.",
"keywords": "",
"snippet": "Loading... Loading...\n\nU.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports continue to su...",
"url": "https://www.benzinga.com/news/earnings/24/05/38637831/wall-street-looks-to-extend-rally-amid-caution-over-fed-speeches-more-earnings-why-this-analyst-thi",
"image_url": "https://cdn.benzinga.com/files/images/story/2024/05/06/Bull-Wall-Street.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2024-05-06T11:09:27.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "0A3M.L",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 14.331194,
"sentiment_score": 0.6841,
"highlights": [
{
"highlight": "<em>BioNTech</em> <em>SE</em> BNTX , Spirit Airlines, Inc. SAVE , TreeHouse Foods, Inc. THS , and Tyson Foods, Inc. TSN are among the notable companies reporting ahead of the market open.\n\n, , , and are among the notable companies reporting ahead of the market open. Those reporting after the close include ADTRAN Holdings, Inc. ADTN , Coty Inc.",
"sentiment": 0.6841,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "46d2386b-a58b-4fbf-9ac2-d73d6fcd16cd",
"title": "BioNTech Slips To Loss In Q1 On Weak Revenues, Backs FY24 View; Stock Dips In Pre-market",
"description": "German Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a loss in its first quarter, compared to prior year's profit with sharply lower net revenues.",
"keywords": "BioNTech, COVID-19, COVID-19 vaccine, Ugur Sahin, BioNTech loss, Biopharmaceutical New Tech",
"snippet": "German Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a loss in its first quarter, compared to prior year's prof...",
"url": "https://www.rttnews.com/story.aspx?Id=3445042",
"image_url": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
"language": "en",
"published_at": "2024-05-06T11:05:13.000000Z",
"source": "rttnews.com",
"relevance_score": null,
"entities": [
{
"symbol": "0A3M.L",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 22.297693,
"sentiment_score": -0.1531,
"highlights": [
{
"highlight": "German Immunotherapy company Biopharmaceutical New Technologies or <em>BioNTech</em> <em>SE</em> (BNTX) reported Monday a loss in its first quarter, compared to prior year's profit with sharply lower net revenues. The company also maintained its fiscal 2024 revenue view.",
"sentiment": -0.1531,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "7fbf6f54-ca5a-422e-86ad-746f7c7d9fb1",
"title": "BioNTech Slips To Loss In Q1",
"description": "Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net loss of 315.1 million euros or 1.31 euros per share for the first quarter, compared to net profit of 502.",
"keywords": "BioNTech, BNTX, Immunotherapy company BioNTech",
"snippet": "Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net loss of 315.1 million euros or 1.31 euros per share for the...",
"url": "https://www.rttnews.com/3445039/biontech-slips-to-loss-in-q1.aspx?type=ern",
"image_url": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
"language": "en",
"published_at": "2024-05-06T11:03:48.000000Z",
"source": "rttnews.com",
"relevance_score": null,
"entities": [
{
"symbol": "0A3M.L",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 26.038311,
"sentiment_score": 0.6124,
"highlights": [
{
"highlight": "Immunotherapy company Biopharmaceutical New Technologies or <em>BioNTech</em> <em>SE</em> (BNTX) reported Monday a net loss of 315.1 million euros or 1.31 euros per share for the first quarter, compared to net profit of 502.2 million euros or 2.05 euros per share in the prior-year quarter.",
"sentiment": 0.6124,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "da67eb92-d3c3-48d8-96d7-24e5562a4125",
"title": "BioNTech veröffentlicht Ergebnisse für das erste Quartal 2024 sowie Informationen zur Geschäftsentwicklung",
"description": "BioNTech ist auf einem gutem Weg, das Jahresziel von zehn oder mehr potenziell zulassungsrelevanten Studien in der Pipeline bis Ende 2024 zu erreichen:...",
"keywords": "Nasdaq:BNTX, BioNTech SE, BioNTech SE, BNTX, Q1 Results, Q announcement, Webcast, Q1, 1. Quartal 2024",
"snippet": "BioNTech ist auf einem gutem Weg, das Jahresziel von zehn oder mehr potenziell zulassungsrelevanten Studien in der Pipeline bis Ende 2024 zu erreichen: weitere ...",
"url": "https://www.globenewswire.com/news-release/2024/05/06/2875667/0/de/BioNTech-ver%C3%B6ffentlicht-Ergebnisse-f%C3%BCr-das-erste-Quartal-2024-sowie-Informationen-zur-Gesch%C3%A4ftsentwicklung.html",
"image_url": "https://ml-eu.globenewswire.com/Resource/Download/b9e2e00e-f790-4d54-a01f-4c85716b01bd",
"language": "en",
"published_at": "2024-05-06T10:45:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "0A3M.L",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 5.054089,
"sentiment_score": -0.5994,
"highlights": [
{
"highlight": "Mai 2024 (GLOBE NEWSWIRE) -- <em>BioNTech</em> <em>SE</em> (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) hat heute die Ergebnisse des am 31. März 2024 endenden Quartals veröffentlicht und Informationen zur Geschäftsentwicklung bekanntgegeben.",
"sentiment": -0.5994,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "73956781-6e66-47c8-9e29-8de83dea71e9",
"title": "BioNTech Announces First Quarter 2024 Financial Results and Corporate Update",
"description": "Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating...",
"keywords": "Nasdaq:BNTX, BioNTech SE, BioNTech SE, BNTX, Q1 Results, Q announcement, Webcast, Q1, 1. Quartal 2024",
"snippet": "Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT3...",
"url": "https://www.globenewswire.com/news-release/2024/05/06/2875667/0/en/BioNTech-Announces-First-Quarter-2024-Financial-Results-and-Corporate-Update.html",
"image_url": "https://ml-eu.globenewswire.com/Resource/Download/b9e2e00e-f790-4d54-a01f-4c85716b01bd",
"language": "en",
"published_at": "2024-05-06T10:45:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "0A3M.L",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 5.054089,
"sentiment_score": 0.4215,
"highlights": [
{
"highlight": "CEST)\n\nMAINZ, Germany, May 6, 2024 (GLOBE NEWSWIRE) -- <em>BioNTech</em> <em>SE</em> (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three months ended March 31, 2024, and provided an update on its corporate progress.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "0A3M.L",
"total_documents": 7,
"sentiment_avg": 0.06130000150629452
}
]
}
Other details
Exchange
- London Stock Exchange
- equity
- N/A
- gb